Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 12
2004 13
2005 10
2006 13
2007 13
2008 11
2009 10
2010 19
2011 15
2012 19
2013 30
2014 21
2015 20
2016 29
2017 23
2018 17
2019 21
2020 19
2021 18
2022 23
2023 23
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Walmsley S, Smith DE, Górgolas M, Cahn PE, Lutz T, Lacombe K, Kumar PN, Wynne B, Grove R, Bontempo G, Moodley R, Okoli C, Kisare M, Jones B, Clark A, Ait-Khaled M. Walmsley S, et al. AIDS Res Ther. 2024 Mar 21;21(1):17. doi: 10.1186/s12981-024-00604-9. AIDS Res Ther. 2024. PMID: 38515183 Free PMC article.
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.
Walmsley S, Nabipoor M, Lovblom LE, Ravindran R, Colwill K, McGeer A, Dayam RM, Manase D, Gingras AC, On Behalf Of The STOPCoV Team. Walmsley S, et al. Vaccines (Basel). 2023 Dec 28;12(1):36. doi: 10.3390/vaccines12010036. Vaccines (Basel). 2023. PMID: 38250849 Free PMC article.
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, Rauch A, Mugglin C, Klein M, van der Valk M, Smit C, Jarrin I, Berenguer J, Lacombe K, Requena MB, Wittkop L, Leleux O, Bonnet F, Salmon D, Matthews GV, Guy R, Martin NK, Spelman T, Prins M, Stoove M, Hellard M; InCHEHC Collaboration. Sacks-Davis R, et al. Lancet HIV. 2024 Feb;11(2):e106-e116. doi: 10.1016/S2352-3018(23)00267-9. Epub 2024 Jan 12. Lancet HIV. 2024. PMID: 38224708
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC).
van Santen DK, Stewart A, Doyle JS, Stoové MA, Asselin J, Klein MB, Young J, Berenguer J, Jarrin I, Lacombe K, Wittkop L, Leleux O, Salmon D, Bonnet F, Rauch A, Mugglin C, Matthews G, Prins M, Smit C, Boyd A, van der Valk M, Sacks-Davis R, Hellard ME; InCHEHC Study Group. van Santen DK, et al. Int J Epidemiol. 2024 Feb 1;53(1):dyad154. doi: 10.1093/ije/dyad154. Int J Epidemiol. 2024. PMID: 38066671 Free PMC article. No abstract available.
Preventative behaviours and COVID-19 infection in a Canadian cohort of people living with HIV.
Hammond K, Lee T, Vulesevic B, Singer J, Needham J, Burchell AN, Samji H, Walmsley S, Hull M, Jenabian MA, Routy JP, Margolese S, Mandarino E, Anis AH, Cooper CL, Costiniuk CT. Hammond K, et al. Among authors: walmsley s. AIDS Res Ther. 2023 Oct 20;20(1):73. doi: 10.1186/s12981-023-00571-7. AIDS Res Ther. 2023. PMID: 37858245 Free PMC article.
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV.
Giguère K, Chartrand-Lefebvre C, Baril JG, Conway B, El-Far M, Falutz J, Harris M, Jenabian MA, Leipsic J, Loutfy M, Mansour S, MacPherson P, Margolese S, McMillan JM, Monteith K, Murray MCM, Pick N, Thomas R, Trottier B, Trottier S, Tsoukas C, Walmsley S, Wong A, Tremblay C, Durand M; Canadian HIV And Aging Cohort Study Group. Giguère K, et al. Among authors: walmsley s. HIV Med. 2023 Dec;24(12):1210-1221. doi: 10.1111/hiv.13550. Epub 2023 Oct 1. HIV Med. 2023. PMID: 37779267
Mpox in people with past infection or a complete vaccination course: a global case series.
Hazra A, Zucker J, Bell E, Flores J, Gordon L, Mitjà O, Suñer C, Lemaignen A, Jamard S, Nozza S, Nori AV, Pérez-Barragán E, Rodríguez-Aldama JC, Blanco JL, Delaugerre C, Turner D, Fuertes I, Leiro V, Walmsley SL, Orkin CM; SHARE-NET writing group. Hazra A, et al. Among authors: walmsley sl. Lancet Infect Dis. 2024 Jan;24(1):57-64. doi: 10.1016/S1473-3099(23)00492-9. Epub 2023 Sep 4. Lancet Infect Dis. 2024. PMID: 37678309 Free article.
Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort.
Cinque F, Saeed S, Kablawi D, Ramos Ballesteros L, Elgretli W, Moodie EEM, Price C, Monteith K, Cooper C, Walmsley SL, Pick N, Murray MCM, Cox J, Kronfli N, Costiniuk CT, de Pokomandy A, Routy JP, Lebouché B, Klein MB, Sebastiani G. Cinque F, et al. Among authors: walmsley sl. BMJ Open. 2023 Aug 22;13(8):e076547. doi: 10.1136/bmjopen-2023-076547. BMJ Open. 2023. PMID: 37607785 Free PMC article.
353 results